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Mbacteriostatic and bacteriocidal protection against gram-
positive organisms that normally cause infections such as
Staphylococcus and Streptococcus.
Our study has several limitations. It is retrospective, from
a single center, and involves separate time periods. Howev-
er, the sample size is large and there were no changes in
perioperative protocols involving antibiotics, surgical tech-
niques, or postoperative care during the study period. Pro-
pensity matching was used to ensure that the risk factors
known to cause sternal infections were evenly matched be-
tween the groups. Although the crossclamp and CPB times
were statistically longer in the no vancomycin group, the
differences are small (5 minutes crossclamp time and 8 mi-
nutes CPB time). Furthermore, our propensity-matched
subset analysis, which took into account crossclamp and
CPB times, showed a 1.1% difference in any sternal infec-
tions, which was statistically different (P ¼ .02).
We conclude that topical vancomycin in combination
with perioperative antibiotics and tight glycemic control
eliminates sternal infections in patients undergoing cardiac
surgical procedures. Consideration should be given to using
topical vancomycin in all patients undergoing a median
sternotomy.
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Dr Thomas J. Vander Salm (Salem, Mass). Thank you, Har-
old, and congratulations for a very important paper.
In 1981, we replaced bone wax with a mixture of topical
thrombin, powdered gel foam, and vancomycin applied to the
cut sternal edges. In 1989, we published a study in the Journal
of Thoracic and Cardiovascular Surgery on 416 patients assigned
to with 2 arms, 1 of which contained the vancomycin in the afore-
mentioned mixture, and the other that did not. We had a 7-fold
reduction in infection in the vancomycin arm, and we have used
it ever since. In our last 2000 patients, we had 1 sternal or medias-
tinal infection. I’m delighted to see the results of this much larger
study in which the vancomycin arm had no infection.
I have 3 questions for you. You address the drawbacks in your
manuscript of this being a retrospective study with 2 arms being
consecutive rather than simultaneous. Do you think it ethically
feasible to conduct this as a randomized or a prospective study?
Dr Lazar. Well, first of all, thank you, Dr Vander Salm, for
coming up here and discussing this paper. A lot of this is based
on your initial findings.
I think that the data from this study and from your previous
studies as well as those of others are so convincing that to try togery c September 2014
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Mdo a prospective randomized study would be unethical and would
not give us any more data that we already have.
Dr Vander Salm. I was hoping you would give that answer.
Your dose of vancomycin applied to the sternum was 10 times
what we have used and you use it twice. How did you arrive at that
dose and should we switch?
Dr Lazar. The doses of vancomycin used in all the papers have
varied. In your report, you used 250 mg. Others have used 1 g in 2
mL of normal saline with excellent results. Recently, Filardo from
Baylor reported using 2 g and 2 mL of normal saline.
There is actually a patent on powdered vancomycin in which the
authors have reported 1 to 3 g per 2 mL of normal saline. We
derived our dose from another institution that was using it, and
that’s why we did the subanalysis in a group of 35 to 40 patients,
to show that even at that dose, there was no significant increase in
vancomycin levels.
I can say that the more you use, the more it has a consistency
that allows you to spread it on the sternum. And I noticed that in
your study, you also used a topical thrombin gel, which gives it
more of a consistency.
Dr Vander Salm. And, finally, I note that you close your me-
dian sternotomies with figure-of-eight cables as do we. The ortho-
pedic literature gives very convincing evidence of increased
susceptibility to infection at fracture sites when there is instability.
Do you believe, as we do, that the figure-of-eight cables mark-
edly increase stability of the sternotomy and thereby account for
some of your good results?
Dr Lazar.We also favor the use of the cables, and we’ve been
using them since 1999. In the earlier group, we did have wound in-
fections with the cables. I think the advantage of the cables is that,
in more fragile sternums, it does give you more of a feeling of sta-
bility without overtightening the sternum. The cables don’t cut
through.
But in those patients who had infections earlier that had cables,
we actually had to take the cables out, whereas if it is a superficial
infection with a wire, we can leave the wire in.
But your point is very well taken, and sternal stability is very
important. And in this latter group of patients in whom I used
the vanco paste, as opposed to what we saw before, we did not
see any evidence of any sternal instability. There was no nonunion.
One theory as to why vanco paste works is that it incites an in-
flammatory response that probably increases fibroblast formation.
This has been studied in basic science models. I think this tends to
make the bone stronger and sturdier and decreases the space for
bacteria to grow.
I think it promotes sternal healing, and at the same time acts as a
bactericidal agent.
Dr Irene J. Cybulsky (Hamilton, Ontario, Canada). We
recently reviewed antibiotic use at our center in Hamilton, and
our infection control people are quite concerned about dosing.
Having reviewed the Society of Thoracic Surgeons’ articles
about antibiotic use, I wonder if you could comment on why
you used both vancomycin and Ancef intravenously, whether
you used the current recommendation of 2 g of Ancef and 3 g
for bigger people, and why you feel that you need to monitor
vanco levels for 6 days when most perioperative therapy need
not be more than a maximum of 48 hours.
Dr Lazar. There are a number of parts to your question.The Journal of Thoracic and CarFirst, the title of the slide was eliminates, and I think that if you
really want to eliminate, and I mean zero percent, no infections, I
think you have to go with perioperative antibiotics and tight glyce-
mic control and the use of the vanco paste. I would be a little leery
about trying to cut back on 1 component because I think since 2007
we haven’t seen a single wound infection on the service.
Dr Cybulsky. So just to follow up about your glycemic control,
we recently audited that, and we have good intravenous control
when we use the drip. But then as soon as the patients leave the
intensive care unit and go to the ward, control goes out of control.
So I wonder if you can comment on the duration of your intra-
venous therapy and how long you monitored good glycemic con-
trol. Did you have it ongoing for 6 days?
Dr Lazar. Our protocol is that they all receive intravenous gly-
cemic control starting in the operating room and for the time that
they’re in the intensive care unit.
We actually have a group of endocrinologists, a glycemic con-
trol monitoring group, who then follow them once they’re off the
drip. So when they leave the intensive care unit, they’re off the
drip. They then go with a short-acting insulin agent, and their
glucose levels are monitored until the time they go home.
But the most intensive monitoring occurs in the operating room
in the first 24 hours after surgery and while they’re in the intensive
care unit. We think that that’s probably the most vulnerable time.
Dr John S. Ikonomidis (Charleston, SC). Harold, congratula-
tions on a terrific study with fantastic and really practice-changing
results.
I don’t know if I missed it, but when you showed the slide on the
incidence of infections, did you include superficial wound infec-
tions as well?
Dr Lazar. Yes.
Dr Ikonomidis. So you’re saying since 2007, you haven’t seen
even a single superficial wound infection with this protocol?
Dr Lazar. That’s true. I don’t think it’s becausewe’re better sur-
geons or our techniques are better. I really do think it’s the
vancomycin.
Dr Ikonomidis.And the second question is that considering our
knowledge about the anatomy of the internal thoracic arteries and
what happens to the vascularization of the sternum when they’re
taken down leads me to wonder whether you were able to demon-
strate a difference in vancomycin levels in patients who had single
mammaries, bilateral mammaries, or skeletonized mammaries. I
wonder if you could comment on that.
Dr Lazar.We don’t have a large experiencewith bilateral mam-
maries. But I can tell you that even with bilateral mammaries, at
least in the last 7 years, we haven’t seen any infections.
As far as the diabetics are concerned, in all the patients who had
their levels measured, they all went back down to subtherapeutic
levels.
Dr Ani C. Anyanwu (New York, NY). I have no disclosures.
Given that, I can understand how you can have a lack of gram-pos-
itive infections with vancomycin, but I find it hard to understand
how you don’t see gram-negatives too. And I would argue that
the results you see are not because of vancomycin. There is some-
thing else you are doing.
Andmy question to you is if everyone in this audience and every
surgeon at this meeting started using vancomycin paste, do you
really think we would eliminate sternal wound infections?diovascular Surgery c Volume 148, Number 3 1039
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MDr Lazar. The answer to your question is yes.
And the second part to your question is that we have operated on
a number of patients in this group with endocarditis due to gram-
negative organisms. I have not seen any infections.
Dr Charles M. Geller (New York, NY). My question is actually
very similar to Dr Anyanwu’s. A number of institutions of late
have been reporting an increased incidence of gram-negative as
well as antibiotic-resistant organism sternal wound infections,
especially in diabetic patients.1040 The Journal of Thoracic and Cardiovascular SurDo you feel that the morewidespread use of topical vancomycin
could contribute to this phenomenon as opposed to actually elim-
inating sternal wound infection?
Dr Lazar. No, I disagree. I know a lot of people are using this.
They just haven’t reported their results.
I find that even our trauma service has used it on trauma patients
and open thoracotomies andwound closures, our orthopedic surgeons
are using it for their implants and putting it around bone surfaces.
They haven’t reported their results, but they have seen no infections.gery c September 2014
